Meldungen zum Thema Health

14.10.2013 – 14:01
Takeda Pharmaceuticals Europe Ltd
Five Scientific Posters Supporting the Efficacy and Tolerability of Once-Daily Lurasidone - A New Atypical Antipsychotic Treatment for Adults with Schizophrenia
Barcelona, Spain (ots/PRNewswire) - On the occasion of the 26th European College of Neuropsychopharmacology Congress (ECNP), with educational financial support provided by Takeda and Sunovion Pharmaceuticals Europe, new data was presented showing both short and long-term efficacy for lurasidone, an atypical ...
mehr
10.10.2013 – 11:32
Mundipharma International
Future Doctors Unprepared to Manage Pain - One of the Most Common Problems They Will Encounter in Clinical Practice, Expert Group Warns
Florence, Italy (ots/PRNewswire) - First ever Europe-wide study reveals that even when undergraduate medical students take a compulsory course on pain, they still only receive on average 12 hours' training There is an alarming lack of dedicated teaching on pain in undergraduate medical schools in Europe, according ...
mehr
09.10.2013 – 13:02
Génome Québec
New Discoveries for Cancer Risk: Researchers Worldwide Take Part in one of History's Largest Scientific Consortium
Montreal (ots/PRNewswire) - Hundreds of researchers from North America, Europe, Australia and Asia have joined together in a consortium to identify the genetic basis of the five most common forms of cancer - breast, prostate, lung, ovarian and colorectal. The group, called the OncoArray Consortium, developed a new ...
mehr
02.10.2013 – 15:26
UBM Live
CPhI Annual Expert Industry Report: Part I
Amsterdam (ots/PRNewswire) - Piramal Enterprises, Fujifilm Diosynth Biotechnologies and Vision Consulting Outline Market Predictions ADCs, multiuse facilities and regulatory transparency and integration seen as the key drivers of tomorrow's healthcare targets CPhI Worldwide [http://www.cphi.com ] and CPhI Pharma Evolution [http://www.pharmaevolution.com ], part of UBM Live's Pharmaceutical Portfolio, announce the release ...
mehr
02.10.2013 – 08:03
European Forum Against Blindness (E-FAB)
New Pan-European Health Economic Study Shows that Eye Diseases Alone Lead to a Total Cost to Society of 20 Billion Euro
Brussels (ots/PRNewswire) - Blindness leads to a significant economic burden on society, estimated to result in economic costs of over 7 billion Euro Investing in screening programs, earlier diagnoses and adequate treatment of retinal conditions can help reduce the economic burden and lead to an improved quality of ...
mehr
26.09.2013 – 07:02
Sanofi Diabetes
Sanofi Announces the CE Mark for JuniorSTAR®, a New Half-Unit Insulin Reusable Pen for People with Type 1 Diabetes
Paris (ots/PRNewswire) - Sanofi announced today at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD), Barcelona, the CE Mark of JuniorSTAR(R), a new halfunit insulin reusable pen that can be used with Lantus(R) (insulin glargine), Apidra(R) (insulin glulisine) or Insuman(R) ...
mehr

25.09.2013 – 15:00
Sanofi
Sanofi announces upcoming launch of MyStar Extra®, the first self- monitoring blood glucose meter with estimated A1c
Paris (ots) - - CE marks obtained for MyStar Extra® and MyStar SylkFeel® lancing device, respectively, enabling commercialization in the European Union - Scientific data presented at EASD 2013 demonstrate robustness and accuracy[i],[ii] of estimated A1c algorithm in MyStar Extra® At the annual meeting of the ...
mehr
25.09.2013 – 11:02
Janssen R&D Ireland
Janssen R&D Ireland Announces Agreement with PATH for Early Development of Rilpivirine in Long-Acting Formulation for Potential Prophylactic Intervention
Cork, Ireland (ots/PRNewswire) - Janssen R&D Ireland (Janssen) announced today it has signed a license agreement with PATH for the early development of the human immunodeficiency virus type 1 (HIV-1) medicine rilpivirine in a long-acting injection (depot formulation) as potential pre-exposure prophylaxis (PrEP) ...
mehr
25.09.2013 – 07:01
Technology iQ
A Viral Market? Insight into the Rise of E-Cigarettes and Vapers from VAPESTICK's Executive Chairman
London (ots/PRNewswire) - "Electronic cigarettes [have] become a phenomenon... as one smoker becomes a vaper and shows their family and friends and they try it. And they love it, and then they show theirs and so on..." Michael Clapper, Executive Chairman of VAPESTICK Doubling in market share annually, electronic ...
mehr
24.09.2013 – 14:03
Sanofi Diabetes
Data Show Sanofi's Lyxumia® Added to Basal Insulin Lowered Blood Sugar Especially when Fasting Plasma Glucose was Controlled
Paris (ots/PRNewswire) - - Findings Consistent with Known Post-Prandial Effect of Lyxumia Supporting Combination with Basal Insulin - Sanofi announced today new GetGoal-L sub-analysis results showing that reductions in HbA1c with Lyxumia(R) (lixisenatide), when added to basal insulin, were greatest in patients with ...
mehr
24.09.2013 – 08:01
Takeda Pharmaceutical Company Limited
Takeda Receives Simultaneous European Marketing Authorization for Three New Type 2 Diabetes Therapies, Vipidia[TM] ? (alogliptin) and Fixed-Dose Combinations Vipdomet[TM] ? (alogliptin and metformin) and Incresync[TM] ? (alogliptin and pioglitazone)
Osaka, Japan (ots/PRNewswire) - Takeda Pharmaceutical Company Limited (Takeda) today announced that the European Commission has granted Marketing Authorization (MA) for Vipidia[TM] (alogliptin), a dipeptidyl peptidase IV (DPP-4) inhibitor, for the treatment of type 2 diabetes patients who are uncontrolled on ...
mehr
23.09.2013 – 10:06
KfW
Improving health outcomes globally: KfW to invest in the Global Health Investment Fund of the Bill & Melinda Gates Foundation
Frankfurt (ots) - - Aims to develop and launch new medicines in developing countries - KfW investing EUR 10 million - Achieving reductions in maternal and child mortality by combatting TB, malaria, AIDS and diarrhoea attractive for private investors On behalf of the Federal Ministry for Economic Cooperation and ...
mehr

19.09.2013 – 08:01
Mundipharma International
Mundipharma Commences COPD Trial
Cambridge, England (ots/PRNewswire) - Mundipharma Research Limited (Mundipharma) announced today a major milestone in the development programme of flutiform(R)(fluticasone propionate / formoterol fumarate) for the treatment of Chronic Obstructive Pulmonary Disease (COPD) with the commencement of a key clinical trial. COPD is a life-threatening lung disease that interferes with normal breathing, estimated to affect at least 64 million people worldwide[1]. The first patient in ...
mehr
12.09.2013 – 12:01
Génome Québec
International Research: Better Sharing of Genetic Information in Human Health
Montreal (ots/PRNewswire) - Since the sequence map of the human genome, the cost of sequencing the genome of an individual has fallen rapidly. This has resulted in a tremendous increase in the amount of human genomic data available to the international research community for the advancement of biomedical research. Yet, there is an absence of international mechanisms to ...
mehr
10.09.2013 – 14:04
UBM Live
CPhI Istanbul Launches as Pharma's Gateway to the High-Growth Markets of Eurasia, Central Asia and MENA Regions
Istanbul (ots/PRNewswire) - New event to act as regional confluence for 22 countries, with Turkey's domestic demand alone forecast to reach $22.8 billion by 2015 UBM Live has today announced the latest addition to its global pharmaceutical events portfolio, CPhI Istanbul 2014 [http://www.cphi-istanbul.com ]. CPhI is ...
mehr
10.09.2013 – 12:22
Astellas European Foundation
Researchers at University Children's Hospital Tübingen, Germany, win the Astellas European Foundation's Transplantation Grant 2013
Chertsey, England (ots/PRNewswire) - Dr Steffen Hartleif and Dr Ekkehard Sturm win $150,000 grant to support their research 'Safety and Tolerability of Immunomodulating Therapy with Mesenchymal Stem Cells in Paediatric Living-Donor Liver Transplantation' The Astellas European Foundation is delighted to announce that ...
mehr
10.09.2013 – 08:02
Camurus
Camurus Receives Option-exercise Milestone for Octreotide FluidCrystal® Product CAM2029
Lund, Sweden (ots/PRNewswire) - Camurus announced today that Novartis has exercised its option to acquire an exclusive license for the further development and worldwide commercialization of CAM2029 for treatment of patients with acromegaly and neuroendocrine tumors (NETs). The license also covers additional future products based on the Camurus' FluidCrystal(R) ...
mehr
07.09.2013 – 09:01
Royal Philips
Philips Respironics Showcases Innovations to Help Improve the Quality of Life for Better Sleep and Breathing at ERS 2013
Barcelona, Spain (ots/PRNewswire) - Today at ERS 2013, the European Respiratory Society (ERS) Annual Congress in Barcelona, Philips Respironics, a unit of Royal Philips , is showcasing patient-centered innovations that represent the future of health care for patients with chronic respiratory diseases. Dedicated to ...
mehr

05.09.2013 – 14:02
Royal Philips Electronics
Focused Ultrasound Foundation Establishes Pioneering Research Initiative in London Under International Center of Excellence Program
London (ots/PRNewswire) - Focused Ultrasound Foundation, Royal Philips, The Institute of Cancer Research, and The Royal Marsden collaborate in center to accelerate progress and establish global standards for focused ultrasound treatment ? enhancing patient care around the world (Photo: ...
mehr
04.09.2013 – 10:02
Biocartis
Biocartis Strengthens Management Team With Chief Commercial Officer
Lausanne, Switzerland And Mechelen, Belgium (ots/PRNewswire) - Biocartis, a molecular diagnostics company, announces today that Ulrik Cordes has joined the company as Chief Commercial Officer (CCO). Ulrik Cordes is an executive with 18+ years of experience in marketing and sales in the med-tech, pharma and biotech industry, of which the past 10 years in top level management roles. "We are delightedtowelcomeUlrik to ...
mehr
04.09.2013 – 10:01
UBM Live
Synergy Between Food and Pharma Driving South America's Economy
Amsterdam (ots/PRNewswire) - CPhI South America nurturing growth throughout the region UBM live announced that this year's recent CPhI South America, which took place from August 6th to 8th, at the Expo Center Norte in Sao Paulo proved to be the foremost event for collaborating two integral industries and providing the opportunity to form symbiotic partnerships with industry leaders to shape the collective markets. (Logo: ...
mehr
03.09.2013 – 14:31
Resverlogix Corp.
Further Analysis of the ASSURE Data Finds a Responder Group for RVX-208 with Statistically Significant Regression of Coronary Atherosclerosis
Calgary, Alberta (ots/PRNewswire) - "In patients with low HDL receiving RVX-208 and Rosuvastatin (Crestor(R)), plaque regression was twice as pronounced as compared to the pre-specified primary endpoint." TSX Exchange Symbol: RVX Resverlogix Corp. today announced the Full Analysis Set (FAS) data from 281 treated ...
mehr
03.09.2013 – 10:03
Breakthrough Prize in Life Sciences Foundation
Online Nominations for 2014 Breakthrough Prizes in Life Sciences are Open
San Francisco (ots/PRNewswire) - Up to five prizes of $3 million each to be awarded The Breakthrough Prize in Life Sciences Foundation announces the opening of online nomination website for its 2014 prizes. The rules and nomination form are available to the public at http://www.breakthroughprizeinlifesciences.org. Anyone can nominate a candidate online and all ...
mehr
22.08.2013 – 15:15
Takeda Pharmaceuticals Europe Ltd
Takeda Launches New Subsidiary in Peru
Zurich (ots/PRNewswire) - Demonstrates Takeda's long-term commitment to the Latin American market Takeda Pharmaceuticals International GmbH ("Takeda") today announced further expansion of its presence in Latin America with the launch of a wholly-owned subsidiary in Peru. Takeda Peru S.R.L. (Takeda Peru or "the Company") will be headquartered in Lima and will be responsible for the sales and marketing of Takeda's products ...
mehr

20.08.2013 – 15:02
Oncopeptides AB
Oncopeptides Initiates Phase II Clinical Study with Melflufen in the Treatment of Multiple Myeloma Patients
Stockholm (ots/PRNewswire) - Oncopeptides AB, a company working to enhance oncology therapies, today announced that the first patient has been dosed as part of a Phase II study in multiple myeloma patients with its drug candidate melflufen (previously called J1). (Logo: ...
mehr
13.08.2013 – 09:32
UBM Live
China's Strong Economic Growth and Healthcare Investments Generate Success for CPhI
Amsterdam (ots/PRNewswire) - China's 'Five Year Plan' underway as attendance at 2013 show rockets CPhI and UBM Live today announced that this year's recent CPhI China 2013, which took place on 25th-27th June at the Shanghai New International Expo Centre, was the most successful exhibition to date. (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a ) Attendance ...
mehr
08.08.2013 – 15:00
Bundesverband Vermögensanlagen im Zweitmarkt für Lebensversicherungen (BVZL) e. V.
BVZL e.V.: International One-day-Symposium on Secondary Markets for Life Insurance
München/Frankfurt am Main (ots) - - Cross-reference: Further Information is available and can be downloaded free of charge at: http://www.presseportal.de/dokumente BVZL International, the Germany-based association for international secondary life insurance markets, will host the One-day-Symposium "Secondary Markets for Life Insurance" on September 23rd, 2013. The ...
mehr
24.07.2013 – 16:02
Safety & Health Expo
Senior Professionals From Across the Industry Flock to Safety & Health Expo 2013
London (ots/PRNewswire) - Following a jam-packed three days at Safety & Health Expo in May, the Industry now prepares for a new era at London's ExCeL in June 2014 UBM Live, organisers of Safety & Health Expo, is celebrating another successful year for Europe's market leading annual exhibition for the occupational health and safety industry. The 2013 show, held in May, ...
mehr
18.07.2013 – 11:21
Informa Exhibitions
Better prospects for the future using modern hospital design / The European Trade Fair "Hospital Build & Infrastructure Europe?
Hamburg/Düsseldorf (ots) - The European trade fair "Hospital Build & infrastructure Europe" will be held in the Congress Center Hamburg from 3 to 4 September 2013. Hospital managers, architects, planners and investors, as well as facility managers, will meet here for the third time to exchange experiences. The ...
mehr
11.07.2013 – 17:19
Echo Pharmaceuticals
Echo Pharmaceuticals Announces Phase 2 Results for Namisol®, Its' Pipeline Product for Oral Administration of D9-Tetrahydrocannabinol and Appoints The Sage Group
Amsterdam, Cambridge, England And Clinton, New Jersey (ots/PRNewswire) - Echo Pharmaceuticals ("Echo") announces that Namisol(R) has completed successfully a Phase II trial with 24 patients suffering from spasticity and pain due to multiple sclerosis (MS). The trial has been conducted by the Centre for Human Drug ...
mehr

Vorherige48495051525354555657Nächste